[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627613":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":11,"locations":20,"responsibleParty":58,"collaborators":11,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":11,"eligibilityCriteria":65,"healthyVolunteers":62,"sex":66,"minAge":67,"maxAge":11,"enrollmentInfo":68,"targetDuration":11,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":11,"overallStatus":23,"whyStopped":11,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"ReValve Solutions Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Single Arm Study","EXPERIMENTAL",null,[13],"Device: ReValve System",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DEVICE","ReValve System","Mitral Valve Replacement Device",[9],[21,39,49],{"facility":22,"status":23,"city":24,"state":11,"zip":11,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Healthycore","RECRUITING","Tbilisi","Georgia","GE",{"type":28,"coordinates":29},"Point",[30,31],44.83412,41.69143,{"lat":31,"lon":30},[34],{"name":35,"role":36,"phone":37,"phoneExt":11,"email":38},"Site Coordinator","CONTACT","+995 32 243 33 43","info@hcore.ge",{"facility":40,"status":23,"city":24,"state":11,"zip":11,"country":25,"countryCode":26,"cosmosGeoPoint":41,"geoPoint":43,"contacts":44},"Tbilisi Heart and Vascular Center",{"type":28,"coordinates":42},[30,31],{"lat":31,"lon":30},[45],{"name":46,"role":36,"phone":47,"phoneExt":11,"email":48},"Study Coordinator","+995 32 218 15 55","info@thvc.ge",{"facility":50,"status":23,"city":24,"state":11,"zip":11,"country":25,"countryCode":26,"cosmosGeoPoint":51,"geoPoint":53,"contacts":54},"Tiblisi Heart Center",{"type":28,"coordinates":52},[30,31],{"lat":31,"lon":30},[55],{"name":46,"role":36,"phone":56,"phoneExt":11,"email":57},"+995 32 250 81 06","info@tbhc.ge",{"type":59,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100627613","phase-1-a-clinical-study-evaluating-the-replacement-of-the-native-mitral-valve-using-the-revalve-system-100627613",false,"NCT07450911","A Clinical Study Evaluating the Replacement of the Native Mitral Valve Using the ReValve System","Key Inclusion Criteria:\n\n* Symptomatic MR (≥3+) due to ischemic and non-ischemic cardiomyopathy etiology determined by assessment of a qualifying transthoracic echocardiogram (TTE) obtained within 60 days and transesophageal echocardiogram (TEE) obtained within 90 days prior to subject registration, with MR severity based principally on the TTE study.\n* New York Heart Association (NYHA) Functional Class II, III or ambulatory IV.\n* Left Ventricular Ejection Fraction (LVEF) is ≥30% (within 90 days prior to subject registration, assessed by the site using any one of the following methods: echocardiography, contrast left ventriculography, gated blood pool scan or cardiac magnetic resonance imaging (MRI)).\n* Age greater than 18 years\n* Left Ventricular End Systolic Dimension (LVESD) is ≤ 65 mm assessed by site based on a transthoracic echocardiographic (TTE) obtained within 90 days prior to subject consent.\n\nKey Exclusion Criteria:\n\n* Untreated clinically significant coronary artery disease requiring revascularization.\n* Need for emergent or urgent surgery for any reason or any planned cardiac surgery within the next 12 months.\n* Status 1 heart transplant or prior orthotopic heart transplantation\n* Cerebrovascular accident within 30 days prior to subject's consent\n* Pregnant or planning pregnancy within next 12 months.\n* Currently participating in an investigational drug or another device study.\n* Evidence of LV or left atrium (LA) thrombus, vegetation or mass\n* Known hypersensitivity or contraindication to procedural, post procedural medication (e.g., contrast solution, anticoagulation therapy) or hypersensitivity to nickel or titanium.","ALL","18 Years",{"count":69,"type":70},20,"ESTIMATED","INTERVENTIONAL",[73],"PHASE1","An evaluation of the ReValve System for treatment of clinically significant mitral regurgitation in subjects determined appropriate for mitral valve surgery.",[76],"Mitral Regurgitation","2026-03-03",{"date":79,"type":80},"2026-03-05","ACTUAL",{"date":82,"type":80},"2026-01-27",{"date":84,"type":70},"2028-01-01",{"name":5,"class":6},3]